Kimberley Lentz
About Kimberley Lentz
Kimberley Lentz is the Executive Director, Early Development Program Lead, Hematology at Bristol Myers Squibb with nearly 20 years of experience in the pharmaceutical industry, specializing in Drug Metabolism and Pharmacokinetics (DMPK).
Current Title and Role
Kimberley Lentz currently holds the position of Executive Director, Early Development Program Lead, Hematology at Bristol Myers Squibb. She is based in Princeton, New Jersey, United States. In this role, she leads the early development programs in the hematology division, applying her extensive expertise in clinical and preclinical research.
Professional Experience at Bristol Myers Squibb
Kimberley Lentz has nearly 20 years of experience in the pharmaceutical industry, primarily at Bristol Myers Squibb. Her journey with the company started in 2000 as a Research Investigator in Pharmaceutics R&D. She quickly progressed through positions of increasing responsibility in Drug Metabolism and Pharmacokinetics (DMPK) from 2001 to 2020. This included roles such as Director and Senior Director of Early Development Program Lead in Fibrosis and Cardiovascular, evidencing her deep expertise and leadership within the company.
Education and Expertise
Kimberley Lentz studied at the University of Maryland Baltimore, bringing a strong academic foundation to her role in the pharmaceutical industry. Her nearly 20 years of experience in DMPK includes specialization in ADME principles for candidate characterization from discovery through clinical development. She has experience in target validation, lead optimization, noncompartmental analysis, PK/PD, human dose projection, and toxicokinetics, among other areas.
Skills and Leadership
Throughout her tenure, Kimberley Lentz has demonstrated outstanding leadership skills. She has a proven track record in change management, skills capability assessment, recruitment, training, talent retention, and matrix team leadership. She has led program strategy and represented her department in broader portfolio-level meetings. Her ability to build strong relationships with various stakeholders—such as Medicinal Chemistry, Biology, Translational Medicine, Drug Safety, Clinical Pharmacology, and Pharmaceutical Development—has been crucial to her success.
Specialization in Drug Metabolism and Pharmacokinetics
Kimberley Lentz has an extensive background in Drug Metabolism and Pharmacokinetics (DMPK). Her expertise includes applying ADME principles, improving metabolic clearance, preformulation/drug product feasibility, and conducting noncompartmental analysis. She is also skilled in human dose projection, DDI assessment, toxicokinetics, and regulatory document preparation. This set of specialized skills has been instrumental in driving the success of various drug development programs at Bristol Myers Squibb.